Shares of Stemline Therapeutics (STML +4.5%) move up again today, hitting another 52-week high....

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Shares of Stemline Therapeutics (STML +4.5%) move up again today, hitting another 52-week high. The stock has soared over 34% since Monday, when its treatment for blastic plasmacytoid dendritic cell neoplasm, SL-401, received an Orphan Drug designation from the FDA.